Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals

Summary

The investigators want to know if ultra-short, effective treatment for latent tuberculosis (TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT) (1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the prevention of TB in human immunodeficiency virus (HIV)-infected individuals.

Conditions

• HIV-infected Participants With Latent TB Infection in High TB Burden Country

Interventions

DRUG

Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

Isoniazid/Rifapentine daily (4 weeks) plus pyridoxine (vitamin B6)

DRUG

Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

Isoniazid/Rifapentine 12-weekly plus pyridoxine (vitamin B6)

Sponsors & Collaborators

• King Chulalongkorn Memorial Hospital

  collaborator OTHER

• Police General Hospital

  collaborator OTHER

• Pranangklao Hospital

  collaborator UNKNOWN

• Taksin Hospital

  collaborator UNKNOWN

• Bhumibol Adulyadej Hospital

  collaborator OTHER

• Klang Hospital

  collaborator UNKNOWN

• Chiang Rai Prachanukroh Hospital

  collaborator UNKNOWN

• Sanpatong Hospital

  collaborator UNKNOWN

• Queen Sawang Vadhana Memorial Hospital

  collaborator UNKNOWN

• Buddhachinnaraj Hospital

  collaborator UNKNOWN

• Maharat Nakhon Ratchasima Hospital

  collaborator OTHER

• HatYai Hospital

  collaborator OTHER

• Srinagarind Hospital, Khon Kaen University

  collaborator OTHER

• Sisaket Hospital

  collaborator UNKNOWN

• The Public Health Centre 28 Krung thon buri

  collaborator UNKNOWN

• The HIV Netherlands Australia Thailand Research Collaboration

  lead OTHER

Principal Investigators

• Anchalee Avihingsanon, MD, PhD · HIV-NAT, Thai Red Cross - AIDS Research Centre

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-08-15

Primary Completion

2038-03-31

Completion

2038-03-31

Countries

• Thailand

Study Locations